The Medical Letter on Drugs and Therapeutics
Copanlisib (Aliqopa) for Relapsed Follicular Lymphoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has granted accelerated approval to copanlisib (Aliqopa – Bayer), an intravenously administered phosphatidylinositol 3-kinase (PI3K) inhibitor, for treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is a common subtype of non-Hodgkin's lymphoma. Copanlisib is the second PI3K inhibitor to be approved for this indication; idelalisib (Zydelig), which is administered orally twice daily, was the first.1

STANDARD TREATMENT — Treatment options for relapsed follicular lymphoma include immunotherapy with an anti-CD20 antibody such as rituximab (Rituxan) plus chemotherapy with an alkylating agent such as bendamustine (Treanda), radioimmunotherapy, and autologous stem cell transplantation. Treatment options are limited for patients whose disease does not respond to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Copanlisib (Aliqopa) for Relapsed Follicular Lymphoma (online only)
Article code: 1545f
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian